On Tuesday, Vir Biotechnology Inc (NASDAQ: VIR) opened higher 3.80% from the last session, before settling in for the closing price of $5.52. Price fluctuations for VIR have ranged from $4.32 to $14.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -18.74%. Company’s average yearly earnings per share was noted 18.32% at the time writing. With a float of $89.12 million, this company’s outstanding shares have now reached $138.06 million.
Considering the fact that the conglomerate employs 408 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.7%, operating margin of -3081.35%, and the pretax margin is -2950.89%.
Vir Biotechnology Inc (VIR) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Vir Biotechnology Inc is 35.53%, while institutional ownership is 53.76%. The most recent insider transaction that took place on Jul 15 ’25, was worth 37,162. In this transaction EVP and Chief Medical Officer of this company sold 6,796 shares at a rate of $5.47, taking the stock ownership to the 108,204 shares. Before that another transaction happened on Jul 17 ’25, when Company’s EVP and Chief Medical Officer sold 3,586 for $5.47, making the entire transaction worth $19,629. This insider now owns 104,618 shares in total.
Vir Biotechnology Inc (VIR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 18.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.85% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
Check out the current performance indicators for Vir Biotechnology Inc (VIR). In the past quarter, the stock posted a quick ratio of 6.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.22, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Vir Biotechnology Inc (VIR)
Compared to the last year’s volume of 1.65 million, its volume of 1.33 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 34.30%.
During the past 100 days, Vir Biotechnology Inc’s (VIR) raw stochastic average was set at 25.54%, which indicates a significant decrease from 58.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was lower than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.16, while its 200-day Moving Average is $7.23. Nevertheless, the first resistance level for the watch stands at $5.80 in the near term. At $5.86, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.99. If the price goes on to break the first support level at $5.61, it is likely to go to the next support level at $5.48. Should the price break the second support level, the third support level stands at $5.42.
Vir Biotechnology Inc (NASDAQ: VIR) Key Stats
There are currently 138,238K shares outstanding in the company with a market cap of 792.10 million. Presently, the company’s annual sales total 74,210 K according to its annual income of -521,960 K. Last quarter, the company’s sales amounted to 3,030 K and its income totaled -120,970 K.
